FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
RegulatoryapprovedLisrayaPositive
AI Analysis
Summary
The FDA has approved Lisraya (brepocitinib), the first oral drug indicated for treating dermatomyositis in adults, marking a significant milestone in treating this rare autoimmune condition.
Outcome Details
FDA approval for oral treatment of dermatomyositis in adults
Importance:9/10
Sentiment:
0.95
FDA approvalfirst-in-classoral therapyrare diseasedermatomyositis
Related Companies
Read the original article
Published by FDA Drugs (New Approvals & NDA) on August 27, 2026 7:11 PM